Physician profile
Stuart Motley
NPI 1851529374
$1,175.47
in general payments reported to CMS, 2019-2025
23 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.16 · 2020: $70.66 · 2021: $95.35 · 2022: $180 · 2023: $350 · 2024: $179 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $770.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $236.41 | 2021-2023 | |
| Insightec,INC | $149.64 | 2023-2024 | Exablate |
| Amgen INC. | $115.52 | 2020-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $100.66 | 2025 | Wegovy |
| Glaxosmithkline, LLC. | $97.96 | 2019-2023 | Arexvy, Shingrix |
| Inspire Medical Systems, INC. | $96.78 | 2024-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.31 | 2021-2023 | Tradjenta |
| Pfizer INC. | $32.89 | 2022 | |
| Novartis Pharmaceuticals Corporation | $32.72 | 2021 | |
| Edwards Lifesciences Corporation | $30.34 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Lilly USA, LLC | $28.45 | 2021-2022 | |
| Medtronic, INC. | $25.94 | 2025 | Inceptiv |
| Sumitomo Pharma America, INC. | $21.84 | 2023 | Gemtesa |
| Horizon Therapeutics Plc | $18.66 | 2023 | Krystexxa |
| Philips North America LLC | $18.14 | 2024 | (Ck6) Holter |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $17.47 | 2022 | |
| Medtronic Vascular, INC. | $17.34 | 2019 | |
| Tolmar, INC. | $16.45 | 2024 | |
| Abbott Laboratories | $15.63 | 2024 | Proclaim |
| Antares Pharma, INC. | $14.58 | 2024 | Xyosted |
| Gilead Sciences, INC. | $14.42 | 2019 | |
| Amarin Pharma, INC. | $11.79 | 2019 | |
| Boston Scientific Corporation | $11.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Motley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.